AI-Powered One-Stop Closed-Loop Chronic Disease Management Service

📌 Background

With China's aging population accelerating, chronic disease management is extending from in-hospital treatment to full-lifecycle care outside the hospital. Policy initiatives are driving the integration of internet hospitals with medical insurance payment loops. AI enables real-time monitoring and tiered interventions, shifting the payer base from patients to B-end entities such as pharmaceutical companies, insurers, and hospitals. A proven benchmark is JD Health, which reported 73.4 billion RMB in revenue for 2025, a 26.3% year-on-year increase (based on public company annual reports). Its internet healthcare and at-home testing services cover 27 cities nationwide, offering over 160 types of at-home testing, providing the necessary fulfillment and payment infrastructure for a closed-loop chronic disease management system.

👤 Target Customers

The primary payers are B-end entities (pharmaceutical companies, insurance firms, hospitals) that purchase platform services to manage their patients/users. C-end patients use core services for free or via membership upgrades.

💰 Revenue Streams

1) B-end SaaS and performance-based incentives: Charging pharmaceutical companies annual SaaS fees for patient management, with additional revenue sharing based on outcomes such as improved medication adherence. 2) C-end value-added subscriptions: Fees for advanced AI reports, exclusive doctor consultations, and health mall benefits. 3) Platform transaction commissions: Commissions on the gross merchandise value (GMV) of drugs and health products. 4) Insurance and employer health management projects: (An opportunity-based stream; the potential scale remains to be determined).

🧮 Cost Structure

Primary costs include AI large model R&D and maintenance, medical team operations, marketing, data compliance and security investments, and cloud infrastructure costs.

🛡️ Moat

1) Data Moat: Long-term accumulation of real-world chronic disease data and continuous AI iteration capabilities, which enhance service precision and create high barriers to entry. 2) Ecosystem Partnerships: Deep integration with the payment loops of pharmaceutical companies, hospitals, and insurers, resulting in high switching costs. 3) Platform Compliance and User Stickiness: Internet hospital qualifications and long-term patient management relationships foster strong trust.

🔑 Keys to Success

• Possessing verifiable AI-driven clinical decision support capabilities and tiered early-warning mechanisms.
• Ability to build Real-World Study (RWS) cooperation models that create closed-loop payment systems for pharmaceutical companies.
• Rapid hospital coverage to accumulate high-value chronic disease data and establish patient trust.

⚠️ Risks

• Lower-than-expected patient conversion rates, leading to decreased willingness to pay from B-end clients.
• Strict data protection policies in public hospitals limiting third-party data integration.
• Ambiguity in legal liability for AI-driven medical decisions, posing regulatory risks.

🏢 Cases

• Weimai: Served 540,000+ patients, implementing 'performance-based' and subscription + pharmaceutical promotion models.
• JD Health Chronic Disease Management: Chronic disease user base grew by 113% over three years, utilizing AI health assistants for real-time analysis, alerts, and hospital connectivity.
• Zhiyun Health: Integrated solutions combining chronic disease membership subscriptions with smart insulin pumps/AI early-warning systems.

📊 SWOT Analysis